Emergencies: Acute Coronary Syndrome | Emergency Medicine and Cardiology

Emergency Room · Clinical Specialties

How it begins

Una revisión profunda y exhaustiva para la toma de decisiones críticas en el departamento de emergencias. Fisiopatología de la placa vulnerable, análisis vectorial electrocardiográfico, interpretación ultra-precisa de biomarcadores cardíacos y protocolos de reperfusión según las últimas guías internacionales.

What it covers

1. Emergencies: Acute Coronary Syndrome
2. Concept, Classification and Universal Definitions
3. · 1.1 · The Fourth Universal Definition of Myocardial Infarction
4. Molecular Pathophysiology of Plaque and the Ischemic Cascade
5. · 2.1 · Formation, Structure and Vulnerability of the Atheroma Plaque
6. · 2.2 · Platelet Activation and Coagulation Cascade
7. · 2.3 · The Myocardial Ischemic Cascade
8. · 2.4 · Myocardial Stunning vs. Myocardial Hibernation
9. Clinical Presentation and Atypical Variants
10. · 3.1 · Semiology of Typical Ischemic Chest Pain
11. · 3.2 · Ischemic Equivalents and Atypical Variants
12. Advanced Electrocardiographic Diagnosis and Equivalent Ischemia
13. · 4.1 · Standard Electrocardiographic Criteria for STEACS
14. · 4.2 · Anatomical Location of Ischemia according to Derivations
15. · 4.3 · Diagnosis of Myocardial Infarction in the Presence of Bundle Blocks
16. · 4.4 · Additional Derivations: Posterior and Right
17. · 4.5 · Patterns of Ischemia Equivalent to High Risk STEACS
18. Cardiac Biomarkers and Analytical Kinetics
19. · 5.1 · High Sensitivity Cardiac Troponins (hs-cTnT and hs-cTnI)
20. · 5.2 · ESC Quick Diagnostic Algorithms (0h/1h and 0h/2h)
21. · 5.3 · Non-Ischemic Causes of Troponin Elevation
22. Risk Stratification in NSTEACS
23. · 6.1 · Clinical Risk Scales: GRACE 2.0 and TIMI
24. · 6.2 · The HEART Scale for the Evaluation of Low Risk Chest Pain
25. · 6.3 · Optimal Times for the Invasive Strategy (Coronary angiography) in NSTEACS
26. Antithrombotic Pharmacotherapy of the Acute Phase
27. · 7.1 · Double Antiplatelet Aggregation (DAPT)
28. · 7.2 · Systemic Anticoagulation in the Acute Phase
29. · 7.3 · Rescue Glycoprotein IIb/IIIa (GP IIb/IIIa) Inhibitors
30. Anti-ischemic, Analgesic and Adjuvant Support Therapy
31. · 8.1 · Oxygen therapy
32. · 8.2 · Vasodilatory Nitrates
33. · 8.3 · Beta Receptor Blockers (Beta-blockers)
34. · 8.4 · Pain Treatment: Opiate Analgesia
35. · 8.5 · Early High Intensity Statins
36. Reperfusion Strategies in STEACS
37. · 9.1 · Temporal Strategy Selection Algorithm
38. · 9.2 · Primary Percutaneous Coronary Intervention (PCI)
39. · 9.3 · Pharmacological Fibrinolytic Therapy
40. · 9.4 · Drug-Invasive Strategy
41. Mechanical Complications of Myocardial Infarction
42. Electrical, Hemodynamic and Cardiogenic Shock Complications
43. · 11.1 · Serious Ventricular Arrhythmias in the Acute Phase
44. · 11.2 · Bradycardias and Conduction Disorders
45. · 11.3 · Post-Infarction Cardiogenic Shock
46. · 11.4 · Right Ventricular Infarction (Flame Right Ventricle)
47. Special Coronary Syndromes: MINOCA, SCAD and Takotsubo
48. · 12.1 · MINOCA (Myocardial Infarction with Non-Obstructive Coronary Arteries)
49. · 12.2 · Spontaneous Coronary Artery Dissection (SCAD)
50. Long-Term Secondary Prevention and Cardiac Rehabilitation
51. · 13.1 · Duration of Double Antiplatelet Aggregation (DAPT)
52. · 13.2 · Blockade of the Renin-Angiotensin-Aldosterone Axis (RAAS)
53. · 13.3 · Lipid Control and LDL-C Targets
54. · 13.4 · Multidisciplinary Cardiac Rehabilitation Programs